KING OF PRUSSIA, Pa., Dec. 21 /PRNewswire/ -- CSL Behring today announced that Helixate(R) FS, its advanced recombinant FVIII (rFVIII) product for the treatment of hemophilia A, is now available in the United States in a new 2000 IU (international unit) vial size. For patients requiring high doses of Helixate FS, the 2000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials.
"Helixate FS, with the new 2000 IU vial, offers patients shorter infusion times, which translates into greater convenience, and will encourage compliance with prescribed treatment," said Robert Lefebvre, vice president and general manager, U.S. Commercial Operations. "The introduction of the 2000 IU vial is a solid example of CSL Behring's ongoing commitment to advancing hemophilia therapy management and improving convenience for patients."
Use of Helixate FS in conjunction with CSL Behring's new HeliTrax(SM) system can improve patient-physician communication and therapy management. The HeliTrax system combines an Internet-based encrypted database for professionals to track treatment and a wireless hand-held electronic diary for patients to log infusions and treatments with recombinant FVIII Helixate FS.
"Combining Helixate FS with HeliTrax may be ideal for the active, growing teen with hemophilia A who needs more factor product," said Jill Leone, RN, CCRP, nurse consultant. "Enhancing the system with the 2000 unit vial dosage will further improve convenience and communication, and enable teens to begin to manage the disease independently."
Helixate FS is packaged with the Mix2Vial, an easy-to-use, plastic, needle-free transfer device with a built-in filter. Use of the Mix2Vial helps minimize the risk of injury and reduces product preparation time.
For more information about Helixate FS and the 2000 IU vial, please
visit http://www.cslbehring.com or call CSL
'/>"/>
| SOURCE CSL Behring Copyright©2007 PR Newswire. All rights reserved |